20/20 GENESYSTEMS, INC.

Most affordable, accessible, and accurate multi-cancer early detection blood test on the U.S. market
Ranked #134 on the 2023 Inc. 5000 list of the “Fastest Growing Companies in America” (#1 in MD)
Partnering with major supermarket chain for in-pharmacy testing beginning in 1H 2024
Early entrant into what is predicted to be a $50B market for multi-cancer early detection testing
Multiple issued or allowed patents in the U.S. and East Asia (available in Downloads section)
Groundbreaking partnership with a leading cancer center + big Asian funding in 1H 2024
Sales volume from our cancer testing more than doubled between 2022 and 2023
Fast Company “World Changing Ideas” Honorable Mention in 2022

Repeat Founder
Founder has started a previous company funded with $2M+, Jonathan Cohen CEOJohns Hopkins MS in Biotech + 25 yrs leading medical diagnostics: partnerships, marketing, IP, & finance. Secured $25M+ in funding & championed pro-biotech legislation. Early pioneer & inventor in multi-cancer early detection blood testing., Michael Lebowitz Ph.D., Chief Scientific OfficerJohns Hopkins Ph.D. (Biochem, Cell & Mol Bio) with 30+ yrs life sciences R&D in cancer Dx & Tx. Adjunct Prof. (Biotech) at Johns Hopkins & U. of MD Baltimore County., Jiming Zhou Ph.D., Chief Operation Officer 20+ yrs academia & industry. Led $330M pharma project. Managed Covid testing for 20/20: 400,000+ tests, peak 3,000+ tests/day., John Compton Ph.D., Board Chair20/20 Chair & BioDx co-founder (sold to Opko). Led BioReference as VP (2007-2013). MIT BS (Bio/Physics), UC Berkeley Ph.D. (Biophysics)., Michael A. RossM.D., Board Member20/20 Director (2016-present). Grew Euclid Systems revenue 5x in 5 years (CEO 2015-2020). GWU Ob-Gyn clinical professor (since 1979). Boards experience in biotech & medical devices. BS (Chem/Bio) & MD., Anne ShiflettActing CFO30+ yrs mgmt, finance & accounting (19 yrs life sciences). Secured $200M+ funding (strategic, PE, VC, etc.). Led company from turnaround to $1.2B sale.